Sarepta Therapeutics Balance Sheet - Annual (NASDAQ:SRPT)

Add to My Stocks
$36.13 $1.7 (4.49%) SRPT stock closing price Jan 17, 2017 (Closing)

A thorough fundamental analysis involves using data from Sarepta Therapeutics balance sheet, apart from other financial statements, to value the business. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Sarepta Therapeutics stock analysis, and provides insights into the firm's financial performance. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. Sarepta Therapeutics had a long term debt of $14.96M at the end of 2015. Sarepta Therapeutics operating cash flow was $-149.46M while Sarepta Therapeutics revenue stood at $1.25M. View latest and last 10 year balance sheet data to check Sarepta Therapeutics financial performance..

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
Marketable Securities122.88M136.79M7.25M---0.17M0.28M0.27M12.99M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets17.38M35.03M3.06M1.53M1.64M1.02M0.77M0.59M0.76M0.73M
Sarepta Therapeutics Total Current Assets
Property Plant & Equipment61.93M58.39M32.37M20.1M20.03M17.03M16.49M18.1M18.64M14.5M
Accumulated Depreciation24.59M19.89M17.32M16.7M15.76M14.96M14.02M12.91M11.81M10.17M
Sarepta Therapeutics Net Property Plant & Equipment
Investment & Advances0.78M0.78M0.64M-------
Other Non-Current Assets-----1.96M2.37M---
Deferred Charges--------3.06M2.55M
Deposits & Other Assets4.47M2.06M0.02M2.77M0.15M0.12M0.12M0.03M0.03M0.03M
Sarepta Therapeutics Total Assets
Notes Payable2.49M2.49M--------
Accounts Payable20.23M12.4M17.63M7.53M9.39M1.31M1.38M2.01M3.02M1.4M
Current Portion Long-Term Debt5.93M0.09M0.09M0.08M0.08M0.08M0.07M0.07M0.07M-
Current Portion Capital Leases----------
Accrued Expenses29.05M17.36M5.04M2.74M2.24M2.01M0.92M1.3M1.17M1.37M
Income Taxes Payable----------
Other Current Liabilities4.57M4.5M13.19M68.52M8.87M42.45M31.12M3.89M5.48M0.37M
Sarepta Therapeutics Total Current Liabilities
Deferred Taxes/Income6.17M6.77M6.83M-------
Convertible Debt----------
Long-Term Debt14.96M3.73M1.57M1.66M1.75M1.84M1.92M2M2.07M-
Non-Current Capital Leases----------
Other Long-Term Liabilities---0.76M0.99M1.09M0.96M0.51M0.43M-
Sarepta Therapeutics Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net0.01M---0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus1.09B926.76M790.42M554.92M340.96M304.81M299.08M266.03M252.73M241.41M
Retained Earnings-899.05M-679.02M-543.23M-431.25M-309.96M-307.64M-275.46M-250.31M-226.35M-203.72M
Treasury Stock----------
Other Liabilities-0.11M-0.09M-------0.01M
Sarepta Therapeutics Shareholders Equity
Sarepta Therapeutics Total Liabilities & Shareholders Equity
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Balance sheet for another ticker

The latest Sarepta Therapeutics stock price, and Sarepta Therapeutics historical stock prices show the stock price movement over time, and the Sarepta Therapeutics PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:
  • Assets: SRPT total assets, which was at $273.78M for 2015 is a balance sheet item representing value of what Sarepta Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities: The total liabilities of Sarepta Therapeutics for 2015 total to $83.43M. Liabilities for a company like Sarepta Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Sarepta Therapeutics Balance Sheet - Key Ratios

Current ratio
Debt to Equity ratio

Annual Balance Sheets For Sarepta Therapeutics Inc Peers

Aviragen Therapeutics balance sheet, BioCryst Pharma balance sheet, Gilead Sciences balance sheet, Juno Therapeutics balance sheet, Ligand Pharma balance sheet